Paldimycin (antibiotic 273ai) and antibiotic 273a2 as well as their individual components, paldimycins A (273aia) and B (273ai)s) and antibiotics 273a2a and 273a2^were synthesized from paulomycin, paulomycin A and paulomycin B, respectively, by reacting with 7V-acetyl-Lcysteine.
The production and isolation of paldimycin (antibiotic 273a2) and antibiotic 273a2 from fermentations of Streptomyces paulus were reported in the first paper in this series.^Extensive chromatographic work and mass spectral analysis indicated that each of the antibiotics consisted of two closely related materials. The components present in paldimycin were designated paldimycin A (antibiotic 273ala) and paldimycin B (antibiotic 273ali3). The two components in antibiotic 273a2 are known as antibiotics 273a2a and 273a2/3. The information discussed in the previous paper1} indicated that both paldimycin and antibiotic 273a2 are produced by S. paulus from paulomycins A and B by addition of two or one molecules of iV-acetyl-L-cysteine, respectively. In order to confirm the proposed structures^( Fig. 1 ) for these antibiotics and to produce the needed materials, we studied the synthesis of paldimycin and antibiotic 273a2. This paper discusses this work and describes the chemical and physical properties of these novel antibiotics. APR. 1987 Experimental
Assay and Testing Procedures
Antibiotic production and purification was measured by a microbiological disc-plate assay procedure with Microcoecusluteus as the assay organism.
Thin-layer Chromatographic Procedures The reaction of paulomycin with iV-acetyl-L-cysteine was followed by TLCon Silica gel G using chloroform -ethanol -water (25 : 30 : 5) or on cellulose powder using pH7.0 phosphate buffer as the solvent systems. The antibiotics present in reaction mixtures or in preparations obtained during purification were detected by bioautography on M. luteus-secded trays.
Spectroscopic Methods 2H NMR spectra were recorded on a Varian XL-200spectrometer operating at 200 MHz.Solutions (ca. 0.4 ml, ca. 0.25 m) of the compounds in dimethyl sulfoxide-d6 or acetone-^were used. 13C NMRspectra were recorded on a Varian XL-200 spectrometer operating at 50.0 MHz.*H and 13C NMR chemical shifts are reported as ppmrelative to tetramethylsilane. Massspectra were obtained on a ZAB-2Fhigh resolution mass spectrometer using a fast atom bombardment (FAB) source.
Analytical High Performance Liquid Chromatography (HPLC) All analytical HPLCchromatography of synthetic paldimycin and antibiotic 273a2 was carried out on a Waters instrument equipped with a Waters 440 UVdetector and operating in the dual pump .98 g (7.75 mmol), was added under stirring to a solution prepared from 25.2 g (150 mmol) of iV-acetyl-L-cysteine in 500 ml of 0.1 m phosphate buffer, pH 7.85. The solution was adjusted to pH 8.7 with aqueous sodium hydroxide and allowed to stand at room temperature for 1 hour. The pH was then adjusted to 3.0 with 2 n aqueous hydrochloric acid and the acidified mixture was extracted three times with 500 ml portions of ethyl acetate. The ethyl acetate extracts were combined, dried over sodium sulfate and concentrated to dryness, to give 14.0 g of crude paldimycin. This material contained (by TLC) paldimycin and traces of antibiotic 273a2 as the only bioactive components. Crude paldimycin was dissolved in 120 ml acetone and the solution was mixed with 1.1 liters of ethyl ether. The precipitated material was isolated by filtration and dried; it was then re-dissolved in 120ml acetone and this solution was mixed with 1.1 liters of ethyl ether. Pure paldimycin, 6.2 g was isolated by filtration and drying. Characterization of this material is described in the characterization section. 2. Paldimycin A: Paldimycin A, 0.91 g, was isolated by the above procedure by reacting 1.0 g of paulomycin A and 4.2 g of iV-acetyl-L-cysteme.
The properties of paldimycin A are described in the characterization section.
3. Paldimycin B: Paldimycin B, 1.1 g, was isolated by the procedure used for paldimycin (see above) by reacting 1.0 g of paulomycin B and 4.2 g of iV-acetyl-L-cystein.
The properties of paldimycin B are described in the characterization section.
Preparation of Antibiotic 273a2 Antibiotic 273a2: Paulomycin (A and B mixture), 2.0 g (2.56 mmol), was added under stirring to a solution prepared from 628 mg (3.84 mmol) of JV-acetyl-L-cysteine in 100 ml of 0.1 m phosphate buffer, pH 7.85. This solution was adjusted to pH8.7 and allowed to stand at room temperature for 20 minutes; it was then adjusted to pH 3.0 and extracted twice with 100 ml portions of ethyl acetate. The ethyl acetate extracts were combined, dried over sodium sulfate and concentrated to dryness to give 2.29 g of colorless amorphous material which contained (by TLC) paldimycin and antibiotic 273a2 as the only bioactive components. This material was dissolved in 20 ml of acetone and the solution was mixed with 450 ml of ethyl ether -Skellysolve B (3 : 1.5). The precipitated material was isolated by filtration and dried (1.56 g). This highly active preparation was found to be a mixture of paldimycin and antibiotic 273a2. Separation of these antibiotics was obtained by counter-double-current distribution as described below.
Separation of Antibiotic 273a2 from Paldimycin: Crude antibiotic 273a2 (1.56 g), obtained as described above, was dissolved in both phases (50 ml) of the solvent system consisting of cyclohexaneethyl acetate-acetone-water (1 : 1 : 1:1). The solution was put in tube 15 (where the lower phase enters the machine) of a 100 -tube all-glass counter-double-current distribution machine. The distribution was analyzed by TLC after 85 transfers. Tubes 10~50 contained antibiotic 273a2 while paldimycin was found in tubes 80~100. Fractions containing antibiotic 273a2 were concentrated to dryness to give, after precipitation from chloroform -Skellysolve B, 440 mgof pure antibiotic 273a2. Characterization of this material is discussed later in this paper.
Antibiotic 273a2a: Antibiotic 273a2a, 390 mg, was prepared by a procedure identical to that described for antibiotic 273a2, from 1.0 g of paulomycin A (1.3 mmol) and 314 mg (1.92 mmol) of JV-acetyl-L-cysteine. The properties of antibiotic 273a2Qr are described in the characterization section. A typical chromatogram is presented in Fig. 9 . A total of 20 runs were made. Corresponding fractions in the shaded area of each of the six peaks (I-VI) observed were pooled. The solutions were acidified (pH~3.5) and the paldimycins present were extracted with methylene chloride. Concentration of the extract to dryness and precipitation from methylene chloride -cyclohexane yielded amorphouscolorless materials which were characterized as indicated in the Results and Discussion section of this paper.
Results and Discussion
Reaction of Paulomycin with iV-Acetyl-L-cysteine In selecting the conditions (solvent, pH, temperature) for the reaction of paulomycin and Nacetyl-L-cysteine we had to consider the properties of paulomycin ; specifically, its weakly acidic nature (pKa\ 7.5), its limited solubility in water and its sensitivity to heating and to both extreme alkaline and extreme acidic environments. Work on the structure of paulomycin2) ( Fig. 1 ) has shown that the antibiotic is transformed easily to paulomycinone, a bio-inactive compound by dehydration of ring A. This reaction, which proceeds slowly in aqueous media at neutral pH, is accelerated at acidic pH's and in solvents like methanol or ethanol. In alkaline media, ring A appears to be reasonably stable. The main reaction which occurs under alkaline conditions is hydrolysis of the paulic acid ester and formation of paulomenol2) which like paulomycinone is bio-inactive.
We decided, therefore, to use 0.1 m aqueous phosphate buffer, pH 8.6, as the solvent and room temperature. Paulomycin has increased solubility in the slightly alkaline solution and the main degradative reactions mentioned above occur very slowly. In order to determine the concentration of the reactants for the quantitative production of paldimycin, a constant amountof paulomycin (200 mg, 0.256 mmol) was added under stirring to different solutions (20 ml) of JV-acetyl-L-cysteine in 0.1 m phosphate buffer, pH $.6, so that the molar ratio of iV-acetyl-L-cysteine to paulomycin was 1 :1 (solution A); 2:1 (solution B); 5:1 (solution C); 10:1 (solution D) and 20:1 (solution E). Reaction mixtures were allowed to stand at room temperature and analyzed at different time intervals by bioactivity determination against M. luteus, UV spectra and TLC. No loss of total bioactivity was observed in each solution for 2 hours. The UVspectra of solutions A, B, C and D observed at 15 minutes were similar to the spectra of paldimycins A and B (Fig. 4) and for practical purposes identical to the spectra obtained at 30, 60 or 120 minutes. Comparison of these spectra to the UV spectrum of paulomycin3) indicates a fast transformation of paulomycin to paldimycin. Thin-layer chromatography of the reaction mixtures showedthat at low TV-acetyl-L-cysteine to paulomycin molar ratios (1 : 1 or 2 : 1), the solutions contained unreacted paulomycin even after 2 hours of reaction time. In addition to paulomycin, paldimycin (Rf~0.15) and antibiotic 273a2 (Rf~0.6) were also present. At higher iV-acetyl-L-cysteine to paulomycin ratios (5 : 1, 10 : 1, 20 : 1) paulomycin is converted rapidly to antibiotics 273aL and 273a2. Finally, at iV-acetyl-L-cysteine to paulomycin ratio of 20 : 1 all paulomycin had been transformed to paldimycin within 1 hour of reaction time.
Preparation and Isolation of Paldimycin and Antibiotic 273a2 Paldimycin (a mixture of A and B), paldimycin A and paldimycin B were prepared by reacting paulomycin (a mixture of paulomycins A and B), paulomycin A or paulomycin B, respectively, with iV-acetyl-L-cysteine (molar ratio 1 :20). The reaction was carried out for 1 hour at room temperature in aqueous buffer, pH8.6. Acidification of the reaction mixture followed by extraction with ethyl acetate yielded the corresponding crude paldimycin which was purified by precipitation from acetone -ether mixture.
Reaction of paulomycin, paulomycin A or paulomycin B with limited amounts of iV-acetyl-Lcysteine (molar ratio 1 : 1.5) for 20 minutes at room temperature in pH 8.6 buffer yielded, after acidification and extraction with ethyl acetate, a mixture of substantial amounts of the corresponding paldimycin and the corresponding 273a2 antibiotic (paldimycin, 273a2 ; paldimycin A, 273a2a; paldimycin By high resolution mass spectrometry (fast atom bombardment). Fromanalytical data. Aqueous KOHwas used as titrant. The physical and chemical properties of paldimycins A and B are listed in Table 1 . The antibiotics are tribasic acids and form mono-, bis-and tri-potassium, sodium or ammonium salts which are soluble in water and concentrations of ca. 150~200 mg/ml. Both antibiotics melt with decomposition at ca. 120°C. The specific rotation of paldimycin A was found to be -31°; paldimycin B had a rotation of -35°. The molecular formulas of C44H64N4O23S3for paldimycin A and C43H62N4O23S3 for paldimycin B were established from analytical data and high resolution FAB-MS (Fig. 2) . The IR spectra of paldimycins A and B, shown in Fig. 3 , are nearly identical and characterized by the For numbering of carbons, see Fig. 1 . Relative to tetramethylsilane. Multiplicity in off-resonance decoupled spectra, s : singlet, d : doublet, t : triplet, q: quartet. Assignments are interchangeable. Abbreviation for iV-acetyl-L-cysteine. absence of the 2050 cm""1 band which is present in the spectra of paulomycins A and B and has been assigned to the isothiocyanate group present in these antibiotics. The UVspectra of paldimycin A and B (Fig. 4) are also identical and contain three peaks at 248, 274 and 321 nm. The maximumat c For groups designation, see Fig. 1 . Paldimycins A and B are separated easily by analytical HPLCusing C-18 reverse phase silica columns and mobile phases consisting of gradients of acetonitrile-phosphate buffer, pH 5.5. Fig. 8 shows a typical chromatogram of paldimycins A and B and of the paldimycin mixture. As in the case of paldimycin produced by S. paulus,l) three peaks are observed in the HPLCchromatogram of either paldimycin. This is due to the formation of two new asymmetric centers at C-2" and C-3" of the paldimycin molecule ( Fig. 1) when two molecules of iV-acetyl-L-cysteine are added to the paulic acid moiety of paulomycin. Four stereoisomers are theoretically possible; it appears, that at least three stereoisomers are formed or separated under the conditions used. Using a semi-preparative HPLCcolumn, 22.2 mg of a mixture of paldimycins A and B was chromatographed. Six peaks were observed, three for each paldimycin A or paldimycin B, and designated I to VI (Fig. 9) . Material from the shaded areas of each peak was isolated and analyzed by HPLC, then characterized by UV, FAB-MS, bio-TLC, and agar diffusion bioassays vs. Micrococcus luteus. Peaks I, II and III yielded materials which showed only one peak in HPLCwith retention times identical to those shown in Fig.  9 for the respective peaks. These materials had properties identical to those of paldimycin B (MW 1,098) while the materials obtained from peaks IV, V and VI, though differentiated by HPLC, behaved like paldimycin A (MW1,112). All material isolated from the six peaks were, within the experimental error, equally active vs. M. luteus. a By high resolution mass spectrometry (fast atom bombardment).
b From analytical data.
Characterization of Antibiotics 273a2a and 273a2/3 Antibiotics 273a2a and 273a2/3 have been also isolated as colorless amorphous compounds with solubilities identical to those of paldimycins A and B. The physical and chemical properties of antibiotics 273a2a and 273a2/3 are listed in Table 5 . The antibiotics are di-basic acids and form salts with sodium, potassium or ammoniumwhich are soluble in water at ca. 150 mg/ml. Both antibiotics melt with decomposition over a wide range of temperatures. The specific rotation of antibiotic 273a2a is -33°; antibiotic 273a2/3 has a rotation of -34°. The molecular formula of C39H55N3O20S2 for antibiotic 273a2a and C38H53N3O20S2 for antibiotic 273a2i3 were established from analytical data and high resolution FAB-MS (Fig. 10) . The IR spectra of antibiotics 273a2a and 273a2/3 ( Fig. ll) are, like the IR spectra of paldimycins, characterized by the absence of the 2050 cm"1 band which is present in the IR spectra of paulomycins A and B, and is due to the isothiocyanate group of these antibiotics. The UVspectra of antibiotics 273a2a and 273a2i3 (Fig. 12 ) are identical and contain absorptions at 246, 270 and 320 nm. The 13C NMRspectra of antibiotics 273a2a and 273a2/3 are shown in Fig. 13 . Lists of the chemical shifts of carbons of antibiotics 273a2a and 273a2iS and the corresponding paldimycin and paulomycins are presented in Tables 2 and 3 . The 13C NMRspectra of antibiotics 273a2a the isothiocyanate carbon,2) is not present in the 13C NMRspectra of antibiotics 273a2 indicating the addition of iV-acetyl-L-cysteine on this group as shown in Fig. 1 . The XHNMRspectra of antibiotics 273a2a and 273a2^, as expected, are very close to those of paulomycins A and B. A list of absorptions due to characteristic features of these antibiotics is presented in Table 6 . Thin-layer chromatographic comparison of antibiotics 273a2, paldimycins A and B and paulomycins A and B is presented in Fig.  7 . As mentioned earlier, no TLCsystems have been developed which would separate antibiotics 273a2a and 273a2£, however, the antibiotics can be differentiated by the HPLCprocedures described in a previous paper in this series.x) Stability of Paldimycins A and B Paldimycins A and B, like the corresponding paulomycins, were found to be very sensitive to heating and to acidic or alkaline environments. Paldimycins, free acids, are reasonably stable when kept at room temperature over desiccants. In moist environments, colorless amorphous paldimycin Aor B in the free acid form, are slowly transformed to a yellowish-orange colored material with corresponding loss of antibacterial activity. However, salts like the paldimycin trisodium salt (U-70,138F) are quite stable. No color formation was observed after storage at roomtemperature for over a year; slight O 5 %) loss of bioactivity was observed during the same period.
In acidic solutions (pH <4.0) paldimycins A and B are transformed to the bio-inactive paldimycinones A and B (Fig. 14, II) by dehydration of ring A. This reaction which results in the formation of strongly orange-red colored solutions, proceeds very slowly at neutral pH's. At pH 3.0 and room temperature, about 22, 57, 71, 75 and 80% of paldimycins A and B are transformed to the corresponding paldimycinones in 4, 24, 48, 72 and 96 hours, respectively. In neutral or slightly alkaline solutions paldimycins A and B are transformed slowly to antibiotics 273a2a and 273a2^ (Fig. 14, III) and to paulomycins A and B (Fig. 14, IV) , respectively.
About 73, 30, 9, 4 and 2.5% of paldimycins A or B remain when solutions of the antibiotics are kept at pH 7.5 and room temperature for 4, 24, 48, 72 and 96 hours, respectively. The amounts of antibiotics 273a2 (a or /3) and paulomycins (A or B) found at these times were: 14 and 5% (4 hours); 15 and 26% (24 hours); 9 and 47% (48 hours); 7.2 and 33% (72 hours); and 7.0 and 19.8% (96 hours), respectively. Several other degradation products were observed by HPLCanalysis of which paulomenols A and B (Fig. 14, V) were easily MIC: Minimuminhibitory concentration Og/ml) determined by agar dilution method in Mueller-Hinton agar (pH 6.0).
Paldimycin (U-70,138) consisted of 60% paldimycin A and 40% paldimycin B. a The CD50 is the dose in mg of drug per kg of body weight given each day that is required to protect 50% of the animals from death. b Paldimycin (U-70,138) consisted of ca. 60% paldimycin A and 40% paldimycin B. c Vancomycin gives CD50 values of 2.3 (1.5-3.5) against UC 6685 and 1.5 (0.9-2.2) against UC 9213.
Gentamicin gives those of 13.2 (8.5-20.6) against UC 6685 and >200 against UC 9213.
recognized. These bio-inactive compounds have been isolated from alkaline hydrolysis of paulomycins AandB.2) Biological Properties The biological properties of paldimycins A and B and antibiotics 273a2a and 273a2i3 will be reported in detail in a paper under preparation. Table 7 shows the in vitro activity of paldimycins A and B and paldimycin (mixture of A and B, U-70,138) against a related group of Gram-positive and Gram-negative bacteria. The antibiotics appear to be equally active against a variety of Staphylococcus aureus strains including those multiply-resistant to /3-lactam, macrolide and lincosaminide antibiotics.* Limited results of in vivo testing of paldimycin and paldimycins A and B are shown in Table 8 . The antibiotics were equally active against three strains of S. aureus. Paldimycins were found non-toxic when administered intraperitoneally.
The LD50's in mice were above 3,000 mg/kg.** Antibiotics 273a2a and 273a2/3 had biological activities identical to those of paldimycins A and B and paulomycins A and B.
